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A B S T R A C T
Systemic/oral corticosteroids (OCS) have been used for decades in the management of acute asthma exacer-
bations and chronically in patients with uncontrolled severe asthma. However, while OCS are effective at
treating acute exacerbations, there is only empirical evidence regarding the efficacy of OCS at reducing the rate
of exacerbations. Evidence, although scarce, is suggestive of high exacerbation rates in severe asthma patients
even when receiving maintenance treatment with OCS. In addition, use of OCS is associated with undesirable
effects. Despite all this, physicians have continued to use OCS for managing severe asthma and acute exacer-
bation due to the lack of availability of effective alternatives. Fortunately, in the last decade several biologics
have been proven safe and effective for patients with uncontrolled severe asthma. This has led to the Global
Initiative for Asthma (GINA) recommending the use of biologics, instead of maintenance OCS, in patients with
severe asthma (GINA Step 5). These include one biologic targeting immunoglobulin E (IgE) (omalizumab), and
different biologics targeting interleukin-5 (IL-5), the IL-5 receptor (IL-5R) or IL-4 receptor α-unit (IL-4R α),
including mepolizumab (subcutaneous), reslizumab (intravenous), benralizumab (subcutaneous) and dupilumab
(subcutaneous).
Omalizumab for the treatment of severe allergic asthma reduces exacerbations, irrespective of blood eosi-
nophil levels. Anti-IL-5/IL-5R biologics are indicated in patients with severe eosinophilic asthma and repetitive
exacerbations, irrespective of the presence or absence of allergy. Recently, an anti-IL4Rα biologic has been
approved by the FDA for eosinophilic phenotype or oral corticosteroid-dependent asthma. Finally, physicians
should consider using biologics as an alternative to chronic OCS therapy.
1. Introduction
Systemic/oral corticosteroids (OCS) have been a mainstay of severe
asthma management. Despite their acknowledged safety risks, the up-
dated Global Initiative for Asthma (GINA 2018) report recommends
short-term low-dose OCS for managing exacerbations and as an add-on
to maintenance treatment with inhaled corticosteroids (ICS) plus long-
acting β2-agonists (LABA) in severe asthma to prevent exacerbations
and for better asthma control [1,2]. However, only empirical data are
available to support the efficacy of OCS in exacerbation reduction.
Furthermore, a recent 20-year observational study in severe asthma
patients showed that those who were OCS-dependent had high mor-
tality (50% of patients died), and had high exacerbation rates [3].
Emerging biologic agents targeting molecular pathways in asthma
have shown significant promise in reducing the need for OCS use [4].
Omalizumab, targeting immunoglobulin E (IgE), reduces exacerbations
in patients with severe allergic asthma, irrespective of blood eosinophil
count [5]. Other biologics targeting specific interleukins (IL), such as
anti-IL5 (mepolizumab and reslizumab), anti-IL5 R α (benralizumab)
and anti-IL4 Rα (dupilumab) also reduce exacerbations in patients with
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severe eosinophilic asthma, without the major safety concerns that
overshadow OCS. As the first-line treatment in severe asthma, GINA
recommends addition of these biologics and/or long-acting muscarinic
antagonists (LAMA) to an ICS and LABA combination [1]. This review
focuses on the current treatment approaches to severe asthma, in-
cluding the burden of systemic corticosteroid-based therapy and the
potential role of omalizumab and other biologics in reducing this
burden.
2. Management of severe asthma: what guidelines recommend
The primary goal of any asthma treatment is to achieve and main-
tain overall asthma control through reduction of both symptom severity
and risk of future exacerbations [6,7]. GINA [1] advocates a continuous
cycle of asthma management (assess – adjust treatment – review re-
sponse) that incorporates a step-wise approach to pharmacological
treatment depending on the level of asthma control and response to
treatment (Fig. 1). This step-wise approach aims to control asthma
symptoms, minimize future risk of exacerbation, and the use of con-
troller and reliever medications.
In general, ICS is the mainstay of asthma management regardless of
the disease severity. Guidelines such as GINA (2018 [1]), National
Heart, Lung and Blood Institute (NHLBI, revised 2007 [8]) and the
British Thoracic Society (BTS, revised 2016 [9]) recommend the use of
OCS in certain circumstances. For example, GINA [1] recommends the
use of low-dose OCS for the treatment of severe asthma exacerbations in
patients who fail to respond to an increase in reliever and controller
medication, deteriorate rapidly or have a history of sudden severe
Fig. 1. The Global Initiative for Asthma (GINA) control-based cycle of asthma care and stepwise approach.
*Not for children aged< 12 years; **For children aged 6–11 years, the preferred Step 3 treatment is medium-dose ICS; #For patients prescribed beclomethasone/
formoterol or budesonide/formoterol maintenance and reliever therapy; †Tiotropium by mist inhaler is an add-on treatment for patients aged ≥12 years with a
history of exacerbations.
Remember to:
• Provide guided self-management education (self-monitoring + written action plan + regular review).• Treat modifiable risk factors and comorbidities, e.g. smoking, obesity, anxiety, etc.• Advise about non-pharmacological therapies and strategies, e.g. physical activity, weight loss, avoidance of sensitizers where appropriate.• Consider stepping up if, uncontrolled symptoms, exacerbations or risks, but check diagnosis, inhaler technique and adherence first.• Consider SLIT in adult HDM-sensitive patients with allergic rhinitis who have exacerbations despite ICS treatment, provided FEV1 is> 70% predicted.• Consider stepping down if symptoms controlled for 3 months + low risk for exacerbations. Ceasing ICS is not advised.
FEV1, forced expiratory volume in 1 s; HDM, house dust mite; ICS, inhaled corticosteroids; IgE, immunoglobulin E; IL-4, interleukin 5; LABA, long-acting β2-agonist;
LTRA, leukotriene receptor antagonists; OCS, oral corticosteroids; SABA, short-acting β2-agonist; SLIT, sublingual allergy immunotherapy.
Reproduced with permission of the GINA 2018 [1].
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exacerbations. However, this use is not desirable, as repeated usage of
systemic corticosteroid is associated with cumulative systemic adverse
events and persistent negative impact on the hypothalamic-pituitary-
adrenal (HPA) axis [10]. Nevertheless, it is difficult to avoid systemic
corticosteroid use completely as it may be the last option for treatment
of acute exacerbations [1,11,12].
Meanwhile, chronic use of OCS as a maintenance therapy should be
assessed based on the potential benefits compared to the high risk of
adverse events, particularly when safe and effective alternatives are
available [13]. If control is not achieved with standard-of–care treat-
ments (high-dose of ICS/LABA and/or LAMA and other controller) for
GINA Step 5 patients, four parameters should be assessed before pre-
scribing maintenance OCS or a systemic corticosteroid burst: (i) alter-
native diagnosis to asthma, (ii) adherence to treatment, (iii) co-
morbidities, and (iv) continuing exposure to the sensitizing agents
[1,14]. Patients with uncontrolled severe asthma should be educated on
asthma self-management, and physicians should use action plans and
have regular follow-ups with their patients. The patients should also be
made aware of the benefits of non-pharmacological management of
asthma including exercise, weight loss, avoidance of triggers and
smoking cessation, concurrent with pharmacological treatment
[1,8,9,15].
Anti-IgE (omalizumab) and IL-5-targeting biologics (mepolizumab,
reslizumab and benralizumab) are recommended in the GINA 2018
report as add-on therapy to LABA/ICS for the long-term control of
asthma in patients with persistent symptoms or exacerbations despite
correct inhaler technique and good adherence with Step 4 treatment
[1]. Omalizumab and anti-IL-5 biologics may provide an opportunity to
reduce the OCS burden in patients with severe allergic asthma and
severe eosinophilic asthma, respectively [16–18]. This potential will be
discussed in more detail later in this review.
3. Systemic corticosteroid in severe asthma: its use and concerns
Although corticosteroids can be effective at reducing airway in-
flammation and treating exacerbations, these treatments are associated
with numerous adverse reactions (Table 1) [19–22]. In many patients
with difficult-to-control asthma (which includes asthma that is un-
controlled due to adherence issues, inappropriate or incorrect use of
medicines, environmental triggers or comorbidities), OCS are often
prescribed as maintenance therapy [13,23]. Chronic OCS users con-
stitute about 3.5% [24], while intermittent OCS users constitute ap-
proximately 40% of the severe asthma population [15]. Hence, chronic
and intermittent uses of OCS need to be discussed.
3.1. Chronic use
Chronic use of OCS is not the optimal treatment when safe and ef-
fective alternatives are available. Use of OCS suppresses the HPA axis
function, with the risk of stress-induced acute adrenal crisis and growth
retardation [25]. It inhibits cortisol and corticotropin secretion via the
pituitary gland [26,27], increases the risk of cataracts [19,28], and can
delay growth and puberty [23]. Although, osteoporosis may be the
most concerning adverse effect with OCS use, it can be managed by
prophylactic intervention [29–32]. Hypertension, type II diabetes and
cataracts are other prominent adverse events [13,33]. Even a small
increase in total cumulative OCS dose increases the risk of diabetes
[34–36]. OCS use is also associated with renal fluid retention and in-
fluences angiotensin II pathways and catecholamine release, which
might lead to uncontrolled hypertension and worsening of cardiovas-
cular disease (relative risk found to be 2.56 compared with controls)
[37].
Two recent, large, retrospective claims-based analyses found a sig-
nificant dose–response relationship between long-term use of systemic
corticosteroid and the risk of developing related complications in pa-
tients with severe asthma [38,39]. In addition, the authors found that
this has resulted in increased burden and costs on the healthcare
system. Another cross-sectional study of two large UK registries found
that 93% of patients with severe asthma had one or more conditions
linked to systemic corticosteroid exposure [40] and that regular daily
corticosteroid exposure was associated with a measurably greater pre-
valence of corticosteroid-associated morbidities compared with subjects
with severe disease receiving frequent rescue courses [41,42]. High
mortality among OCS-treated patients with severe asthma has also been
reported [40]. Previous systematic reviews showed that OCS are a
common cause of adverse events in heterogeneous patients, even at
regular doses; high dose of OCS for a short period, or prolonged use of
small dose can have clinical impact. Sullivan et al. [37] showed that
intermittent use of OCS (≥4 OCS prescriptions/year was associated
with 1.29 times the odds of experiencing a new adverse event within
the year. Patients with asthma who were treated with OCS for> 30
days/year have a greater overall risk of possible corticosteroid-related
adverse events compared with the patients with no OCS use [43]. Some
patients, can develop Cushingoid appearance with chronic adminis-
tration of prednisone at 5mg/day dose [44]. It was also observed that
the dose response relationship of oral corticosteroids, particularly in
relation to fractures showed that of all forms of OCS treatment, the
highest doses (approximately> 7mg/day prednisolone equivalent)
were universally found to be associated with the largest incidence of
fractures [19].
3.2. Intermittent use
In severe asthma, intermittent systemic corticosteroid use is gen-
erally recommended for managing acute asthma exacerbations [1].
Asthma control and exacerbation reduction are the aims of treatment
with all biologics. If we reduce exacerbations, we decrease the
Table 1
Reported adverse reactions associated with long-term systemic corticosteroid
use.
Common (≥1/100c) Less common (1/100–1/1000c)
Adrenal suppression (high doses for
prolonged periods)b
Aggravation of epilepsy
Anxiety Aggravation of schizophrenia
Bruising Corneal or scleral thinning
Behavioral changes (hyperactivity,
irritability, and aggression)
Ecchymosis
Candidiasis Facial erythema
Cataracts Hypersensitivity reactions
(including anaphylaxis)
Cushing's syndrome Hypokalemiaa
Depression Impaired healing
Diabetesa Malaise
Dyspepsia Menstrual irregularities and
amenorrhea
Exacerbation of ophthalmic viral or fungal
disease
Muscle weakness
Growth retardationb Papilledema
Headache Peptic ulceration
Hyperglycemia Petechia
Hypertensiona Sodium and water retention
Increased susceptibility to and severity of
infectiona
Vertebral and long-bone fractures
Leukocytosis Vertigo
Nausea
Neutrophilia
Reduced bone mineral density/
osteoporosisa
Skin atrophy
Skin thinninga
Suppression of skin test reactions
Weight gain
a Particularly common adverse effects in elderly patients.
b Particularly common in children.
c Frequency of cases in corticosteroid-exposed individuals.
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intermittent systemic corticosteroid use. Studies on all biologics have
generated solid data in controlling the disease and decreasing its ex-
acerbations. Omalizumab significantly reduced the rate of clinically
significant severe asthma exacerbations (26% in the INNOVATE study)
in severe allergic asthma [46]. The eXpeRience registry also revealed
substantial reductions in clinically significant severe asthma exacerba-
tions after 1 (80.5%) and 2 years (89.9%) of omalizumab treatment
[47]. The recently published GINA pocket guide for severe asthma is
still recommending omalizumab for severe allergic asthma with posi-
tive skin prick testing per specific IgE and total serum IgE and weight
within dosage range. It additionally adds as positive predictive factors
childhood onset asthma, FeNO ≥20 ppb, allergen driven symptoms and
blood eosinophils ≥260 cells/μL. It does not consider separately the
overlap group of allergic and eosinophilic severe asthmatic patients, but
implies starting first with anti-IL5/anti-IL5R treatment in patients with
blood eosinophils ≥300 cells/μL, nasal polyposis, adult onset asthma,
more exacerbations in the previous year [48].
4. Corticosteroids: a focus on children
4.1. ICS use
ICS are the cornerstone of care for asthma of all severities; however,
use of high-dose ICS in children warrants caution. Pre-pubertal high-
dose ICS exposure during the first 1–2 years of treatment has been as-
sociated with negative growth outcomes such as decreased adult height,
although this is not progressive or cumulative [49]. Indeed, the use of
high-dose ICS may be avoided by adding-on an alternative treatment
like registered biologics, as recommended by GINA [1] and as shown in
some studies [50]. We will not assess the benefits and risks of high-dose
ICS in this review.
4.2. OCS use
Recent reviews of asthma prescribing patterns show that OCS are
widely prescribed in children [51]. In a 2015, US-based study of 69,056
children with asthma, 42.1% children had ≥1 OCS prescription, 9.9%
had ≥2 OCS prescriptions, and 3.3% had ≥3 OCS prescriptions [52]. A
separate study in US children reported that patients with non-severe
(N=624,219) and severe asthma (N=34,950), 23% and 64% of pa-
tients, respectively, were prescribed OCS [41]. A Dutch study found a
higher OCS prescription incidence rate in early childhood (0–5 years)
compared with school age children (6–10 years) [51]. In addition, so-
cioeconomic status is a factor: poor children seem to receive up to 2.55
times more systemic corticosteroid prescriptions than urban children
who are not poor [53].
5. Benefits of OCS in the pediatric asthma population is
controversial
Few studies have examined the therapeutic benefit of using systemic
corticosteroid and the findings are conflicting. A recent review (2016)
of 11 studies examined the use of OCS in the treatment of recurrent
wheezing in infants, toddlers, and preschool children. When the ana-
lysis was stratified by trial setting, differences in benefits and risks of
OCS use were identified; among the emergency department studies,
children who received OCS had a 42% lower risk of hospitalization,
indicating a therapeutic benefit for OCS. However, among the out-
patient studies, children who received OCS had a>2-fold higher risk of
hospitalization compared with those who received placebo [54]. Even
parent-initiated OCS use in an asthma exacerbation failed to improve
outcomes such as emergency department visits, hospital admissions,
unscheduled medical reviews, symptom scores, bronchodilator use,
parent and patient impressions, physician assessment, or days lost from
work or school; rather, it increased hospitalizations among those re-
ceiving OCS [55].
Among preschool children, OCS use for acute exacerbations in
asthma is well documented [37,56–60], but as explained above, there is
a related cumulative negative burden on both the current and future
health of patients with asthma from OCS exposure that is independent
of the dose and duration of treatment [37]. As such, so-called OCS-
sparing strategies that reduce the burden of OCS use in patients with
asthma are likely to improve patient outcomes by reducing the risks
associated with OCS use [37].
6. Biologics: an alternative to systemic corticosteroids in severe
asthma
A few biologics are currently licensed for use in severe asthma but
are often indicated for use in specific asthma phenotypes. The GINA
report recommends use of biologics (anti-IgE, anti-IL-5) as preferred
controller options for Step 5 patients before the use of OCS [1]. Anti-IgE
therapy (omalizumab) is recommended for adult patients and children
aged ≥6 years with moderate or severe allergic asthma that is un-
controlled on GINA Step 4 treatments before the use of OCS (Fig. 1)
[1,47]. This recommendation is given in accordance with the GINA
‘Evidence A’ category, which reflects the large amount of data available
[1]. In severe allergic asthma, omalizumab has been studied for more
than 15 years in both randomized controlled and observational clinical
trials that showed that omalizumab provides clinical benefits and re-
duces OCS use in patients with severe allergic asthma [1,18].
In addition to anti-IgE treatment, treatments targeting the IL-5
pathway, such as mepolizumab, reslizumab and benralizumab, are in-
cluded in the latest GINA update and dupilumab was recently approved
by the FDA. These biologics are recommended as add-on therapy for
patients with severe eosinophilic asthma that is uncontrolled on Step 4
therapy (Evidence B – based on the results of randomized clinical trials
[RCTs] and meta-analyses) [48]. Omalizumab, mepolizumab, benrali-
zumab and dupilumab have demonstrated OCS-sparing capacity.
Omalizumab [17,60–65] demonstrated its OCS sparing effectiveness in
severe allergic asthma, mostly in real-world evidence (RWE) observa-
tional studies across various patient population spanning more than 15
years and some RCTs [46,66–69]. Whereas, relatively newer mepoli-
zumab [16], benralizumab [70] and new dupilumab [71] demonstrated
OCS sparing effect in RCTs in order to include OCS sparing effect in
their label. Outcomes from key clinical trials involving omalizumab,
mepolizumab, reslizumab, benralizumab and dupilumab are summar-
ized in Table 2. Current evidence suggests that these anti-IL-5 treat-
ments are safe and effective in the treatment of severe eosinophilic
asthma [1,72–81]. However, further prospective studies are warranted
to evaluate efficacy (mainly related to eosinophil reduction and de-
pletion) and safety of these biologics in children [8 1]. Table 3 sum-
marizes, within the limitations of existing label information at the time
of writing this paper, the attributes of the biologics currently licensed
for use in patients with severe asthma.
7. Omalizumab in pediatric asthma
Among biologics, omalizumab is registered for use in children aged
≥6 years with severe allergic asthma [1]. Deschildre et al. and Rottem
et al. demonstrated an OCS-sparing effect of omalizumab, an im-
provement in lung function and health status and reduced exacerba-
tions, while showing a good safety profile [61,62]. Hence, chronic and
intermittent (related to exacerbations) OCS exposure is reduced. In
addition to control of exacerbations in patients with severe asthma, the
PROSE study showed that omalizumab prevents seasonal autumn viral-
induced exacerbations (needing systemic corticosteroid) by blocking
the dendritic cell (DC) IgE, the secretion of interferons by DC, which is
key against viral infection. When giving a short course of omalizumab
to children before school entry, we observed> 80% reduction in ex-
acerbations in children who previously exacerbated [82].
A number of RWE studies have observed steroid-sparing effects with
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Table 2
Main findings from key studies that aimed to reduce the use of oral corticosteroids (OCS).
Citation Design Main findings
Omalizumab
Berger et al. [91] 28-week, double-blind, RCT with a 24-week open-label extension in
children (N=225) with moderate-to-severe allergic asthma
requiring ICS
There was a substantial reduction in ICS use in the double-blind period
that was maintained in the open-label phase
Almost all patients who withdrew ICS at the end of the core study
remained ICS-free at the end of the extension period
Teach et al. [82] Three-arm, randomized, double-blind, double placebo controlled,
multicenter clinical trial in asthmatic children aged ≥6 years with
≥1 recent exacerbation
A subgroup analysis from the PROSE study showed that omalizumab was
significantly more efficacious than both placebo and ICS burst in
patients with an exacerbation during the run-in phase
Deschildre et al. [61] One-year observational survey of atopic children and adolescents
(N=104) with severe allergic asthma who were given omalizumab
as an add-on therapy to high level maintenance treatment
Over the year on treatment, a 30% reduction in ICS dose was reported
(P < 0.0001).
Brodlie et al. [17] Interventional study in 34 children with severe asthma receiving
maintenance oral prednisolone
There was a median daily prednisolone dose reduction from 20mg to
5mg (P < 0.0001), including 7 children who stopped taking
prednisolone completely
Rodrigo et al. [100] Systematic review examined 8 RCTs (3429 participants), which
compared subcutaneous omalizumab with placebo as an add-on to
corticosteroids (inhaled or oral) in patients with allergic asthma. Six
studies were in adults and adolescents (aged ≥12 years) and two
were in children (aged < 12 years)
Compared with placebo, omalizumab resulted in significantly fewer
asthma exacerbations (RR 0.57, 95% CI 0.48 to 0.66, NNTB=10, 95%
CI 7 to 13). Omalizumab significantly reduced asthma exacerbations per
patient (WMD −0.19, 95% CI −0.23 to −0.14; eight RCTs),
hospitalization rates (RR 0.44, 95% CI 0.23 to 0.83; 5 RCTs), inhaled or
OCS dose (more than 50% dose reduction RR 1.34, 95% CI 1.23 to 1.46;
4 RCTs) and steroid use (complete withdrawal RR 1.80, 95% CI 1.42 to
2.28; 4 RCTs)
Molimard et al. [65] Real-world evidence study assessing prescriptions of omalizumab for
> 16 weeks by French and German clinicians to patients with severe
persistent allergic asthma (N=346)
Following omalizumab therapy, 50.6% patients on OCS at baseline
reduced/stopped OCS dose at the time of data collection; 20.5% stopped
and 30.1% reduced OCS. In all patients receiving maintenance OCS at
baseline, mean reduction from baseline in daily OCS dose was 29.6%
(7.1mg prednisolone). In patients who reduced/stopped maintenance
OCS, mean reduction from baseline in daily OCS dose was 74.3%
(15.4mg prednisolone).
Siergiejko et al. [63] Randomized, open-label, placebo-controlled trial of omalizumab
added to optimized asthma therapy, compared with standard therapy
alone over 34 weeks (N=82)
Change from baseline in mean maintenance OCS dose at the end of the
study was significantly greater in the omalizumab-treated group
compared with the standard therapy group (mean OCS dose at baseline
[13.1mg] vs at Week 32 [8.4mg]; change from baseline, −45%;
P= 0.002). Significantly more patients (n= 59) treated with
omalizumab reduced or stopped OCS use at Week 32
Rottern et al. [62] Small study in a real-life setting in Israel that compared use of OCS in
patients taking omalizumab with those taking placebo (N=33)
The number of patients who used OCS significantly decreased for those
receiving omalizumab therapy (84.8% vs 57.6%, P < 0.003), as did the
median dosage of OCS for 33 patients (753mg vs 662mg; P < 0.002)
Lafeuille et al. [64] Retrospective cohort study of patients (N=644) with uncontrolled
asthma based on a US health insurance claims database
Data showed 53.3% of those who initiated omalizumab therapy were
able to reduce their OCS use
Braunstahl et al.– the
eXpeRience registry [47]
2-year multinational, observational study of 943 patients with
uncontrolled allergic asthma who were taking omalizumab, 263 of
whom were also receiving maintenance OCS therapy
The proportion of patients (n=131) who had maintenance OCS therapy
was lower at Month 24 (14.2%) compared with Month 12 (16.1%) and
baseline (28.6%). The mean total daily OCS dose (prednisolone
equivalent) decreased between baseline (15.5mg) and Month 12
(7.7mg), and continued to decrease between Months 12 and 24 (5.8mg)
Mepolizumab
Nair et al. [101] Randomized, double-blind 26-week trial involving 20 patients with
persistent airway eosinophilia and symptoms despite prednisone
treatment. Patients received monthly intravenous infusions of either
mepolizumab (750mg) or placebo
Patients receiving mepolizumab were able to reduce their prednisone
dose by a mean (± SD) of 83.8 ± 33.4% of their maximum possible
dose, as compared with 47.7 ± 40.5% in the placebo group (P= 0.04).
The mean dose of prednisone was reduced from 11.9 to 3.9 mg in the
mepolizumab group and from 10.7 to 6.4mg in the placebo group
(median reduction in the two groups, from 10 to 5mg) (P= 0.11)
Bel et al. [16] Placebo-controlled, double-blind, randomized study of patients
(N=135) with severe eosinophilic asthma who had at least a 6-
month history of systemic corticosteroid maintenance treatment
prior to study initiation
In the pre-specified primary outcome, more patients in the mepolizumab
group than in the placebo group had a reduction of 90–100% in the OCS
dose (23% vs 11%) and a reduction of 70 to less than 90% (17% vs 8%)
during Weeks 20–24 of the study
In the placebo group, 56% patients had no reduction in OCS dose, had a
lack of asthma control, or withdrew from the study, than patients in the
mepolizumab group (36%). Further analyses of these data show an
overall odds ratio for a reduction in the OCS dose in the mepolizumab
group was 2.39 (95% CI, 1.25 to 4.56; P=0.008)
Benralizumab
Nair et al. [71] 28-week randomized, double-blind, parallel-group, placebo-
controlled trial in severe asthmatic patients (N=220) who had been
treated continuously with oral glucocorticoids for 6 months or more
before enrollment and were receiving oral prednisone or
prednisolone at the trial entry
The two benralizumab dosing regimens significantly reduced the median
final OCS dose from baseline by 75%, compared with a reduction of 25%
in the OCS doses in the placebo group (P < 0.001 for both
comparisons). The odds of a reduction in the oral glucocorticoid dose
were more than 4 times as high with benralizumab as with placebo.
Benralizumab administered every 4 and 8 weeks resulted in an annual
asthma exacerbation rate by 55% and 70%, respectively, lower than the
rate with placebo.
Dupilumab
(continued on next page)
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omalizumab in severe allergic asthma (up to 25mg/day reduction)
[16,17,47,61–64,83–97]. Also, RCTs like EXALT [62], Study 011 [68],
INNOVATE [46], and ETOPA [69] evaluated OCS sparing effect of
omalizumab. If at 4 months of treatment there is no response (global
evaluation of treatment effectiveness [GETE] score) [98], omalizumab
should be stopped following the early stopping rule. If the blood eosi-
nophils are high (the new GINA pocket guide suggests blood eosinophils
≥300/μL) in adolescents older than 12 years, anti-IL-5 biologics (me-
polizumab, benralizumab) targeting eosinophilic asthma should be in-
itiated [45,98] and the response should be assessed after four months
[48]. Nevertheless, treatment with any biologics are subjected to pa-
tients’ allergic phenotype, in terms of IgE and/or blood eosinophil le-
vels and cannot be distinguished as first-line or second-line therapies
[99].
8. Other alternatives to systemic corticosteroid
Apart from anti-IgE, anti-IL-5, anti-IL5 R and recently approved
anti-IL-4Rα [102] therapies and several other treatments that may also
represent OCS-sparing options for patients with severe asthma are in
development. Those that have successfully reached Phase II and Phase
III clinical trials include biologic agent targeting anti-thymic stromal
lymphopoietin (TSLP, tezepelumab) [103], and non-biologic agents,
such as the prostaglandin receptor D2 (DP2) antagonist, fevipiprant
[104] Fig. 2 shows the key immunological pathways of asthma together
with the targets for existing and new treatments.
9. Severe asthma management: the CARE pathway
For patients who are already receiving OCS, use of biologics may
allow the OCS dose to be gradually reduced and eventually withdrawn
[11]. In severe allergic asthma, following the integrated care pathway
guidance on the choice of biologics proposed by Bousquet et al. [45]
treatment could start with omalizumab and response must be assessed
at 4 months of treatment (Fig. 3). This guidance in the integrated care
pathway is not based on effectiveness, since the other biologics are also
proven effective, but in 15 years of safety data, age (could be given in
children) and data that in case of [45] unresponsiveness to omali-
zumab, anti-IL5 treatment could also be initiated directly [105].
However, the new GINA pocket guide suggests to also considering
starting first with anti-IL5/anti-IL5R treatment if blood eosinophils
≥300/μL, having in mind that nasal polyposis, adult onset asthma,
more exacerbations the previous year and higher blood eosinophils
could predict responsiveness which should be assessed in four months
[48,106]. Our goal should be to minimize OCS misuse in patients with
severe uncontrolled asthma and help assist physicians in determining
the most appropriate biologic to help the patient control their asthma.
10. What if biologics are not effective?
For patients who do not respond to biologics, high-dose and/or
long-term corticosteroid treatment will be required to effectively con-
trol their asthma, as per guidelines. Although, OCS is widely used in T2
inflammation, effectiveness of OCS in non-type2 asthma is unclear. A
recent study in children difficult asthma showed comparable efficacy of
OCS in terms of improvement in lung function, irrespective of sputum
eosinophils levels [107]. In these instances, physicians will need to
consider the potential for unwanted adverse effects and attempt to
minimize exposure to steroids, especially in female, children, adoles-
cent and elderly patients who are more at risk of adverse effects. To
minimize the potential for unwanted adverse effects, the lowest effec-
tive dose of OCS should be administered for the minimum amount of
time to achieve control [23,108]. Therefore after avoiding exposures
(i.e. tobacco smoke) and adding tiotropium or macrolide (if not already
tried), we should consider add-on low dose OCS, but implement stra-
tegies to minimize side-effects [48]. Bronchial thermoplasty (BT) may
also be an option, but is recommended only in the context of a sys-
tematic registry or a clinical study [15]. Previous findings showed that
BT was associated with long-term blood eosinophil suppression [109]
and reduction in OCS dose [110] in patients with uncontrolled asthma.
Hence, BT may be an option for asthmatics inadequately controlled by
biologic therapy [110].
If all treatments are unsuccessful, where possible, patients could be
included in ongoing clinical studies of new severe asthma medications,
like anti-TSLP (tezepelumab [103], Phase II completed; ClinicalTrials.
gov Identifier: NCT03347279), anti-IL-33 [111], anti-IL-4 and or fevi-
piprant (Phase III ongoing), a DP2 antagonist [104].
11. Conclusions
Although OCS therapy is an option in the treatment guidelines for
patients with severe asthma, the consequences of chronic use, or even
systemic corticosteroid bursts, should be considered and balanced with
the therapeutic efficacy of these drugs. Indeed, as a lot is already known
about the adverse effects of OCS, their use in patients with severe
asthma may be considered inappropriate. Biologics offer a well-toler-
ated and effective solution to the problems observed with systemic
corticosteroid use in specific phenotypes of severe asthma and offer
many benefits. Hence, biologics such as omalizumab, and anti-IL-5
targeting biologics should be considered as alternatives to OCS in well-
selected patients with uncontrolled severe asthma.
Omalizumab has 15 years of clinical experience and safety data in
severe allergic asthma, and more than 800,000 patient-years of ex-
posure [18], with a clear allergic indication in terms of positive skin test
or in vitro reactivity to a perennial aeroallergen and in addition the
serum total IgE levels in the range of 30–700 IU/mL (in the US) or ≥30
to ≤1500 IU/mL (Europe) in adults and children ≥12 years and<
1300 IU/mL for children ≥6 years. It can reduce exacerbations, control
the disease and reduce the OCS burden Therefore, it may be offered as
the first choice in patients with severe allergic asthma, as shown by the
integrated clinical pathway guidance [45]. Omalizumab also has a well-
defined early stopping rule in four months if the response to treatment
is not good according to GETE. Our approach is not based on effec-
tiveness, as IL-5 targeting biologics have been also proved effective in
reducing exacerbations.
Physicians rightly are very conscious of the danger of systemic
corticosteroid overuse in patients with severe asthma. Considering the
existing data on efficacy, real-life effectiveness and safety of several
biologics in severe asthma, physicians should consider these treatments,
and either prescribe the appropriate biologic therapy or alternatively,
refer patients with corticosteroid-dependent severe asthma to a spe-
cialist.
Table 2 (continued)
Citation Design Main findings
Rabe et al. [72] 24-week randomized, double-blind, parallel-group, placebo-
controlled trial in patients with steroid-dependent severe asthma
(N=210)
Compared with placebo, dupilumab reduced 70% OCS dose while
decreasing the rate of severe exacerbations and increasing the FEV1
CI, confidence interval; ICS, inhaled corticosteroid; OCS, oral corticosteroid; NNTB, number needed to treat for benefit; RR, risk ratio; WMD, weighted mean
difference.
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